Dr. James Brandt
Location
Areas of Expertise
About Me
Dr. James David Brandt is an ophthalmologist specializing in glaucoma care at UC Davis Health. He serves as the Director of the Glaucoma Service and holds the Daryl & Opal Geweke Endowed Chair in Glaucoma. Dr. Brandt's philosophy emphasizes patient education, believing that informed patients are empowered to partner in their care decisions. He treats adults and children with various forms of glaucoma, including primary open-angle glaucoma and ocular hypertension.
Dr. Brandt has a particular clinical focus on glaucoma in infants and children. He teaches pediatric glaucoma surgical techniques worldwide through his work with Orbis International, traveling to developing countries to care for children with this rare condition. He has directed numerous clinical and surgical trials in glaucoma, contributing to advances in both medical and surgical treatments such as trabeculectomy, tube shunt surgery, and microshunt procedures. Dr. Brandt approaches each patient encounter with the goal of creating a collaborative treatment plan that aligns with their individual needs.
Training

Glaucoma (Clinical)
1989Thomas Jefferson University
FellowshipOphthalmology
1988University of Southern California / Los Angeles County Hospital / Doheny Eye Institute
Residency
Post-doctoral Research (Ocular Cell Biology)
1985Harvard Medical School
Fellowship
General Surgery Internship
1983University of Minnesota
Residency
M.D
1982Harvard Medical School
Medical School
B.S., Biology
1978Yale University
Undergraduate
Awards & Honors
Humanitarian Award
2018American Glaucoma Society
Lifetime Achievement Award
2015American Academy of Ophthalmology
Clinician-Scientist Lecturer
2012American Glaucoma Society
Publications & Press
Postoperative Complications in the Primary Tube Versus Trabeculectomy Study During 5 Years of Follow-up
Ophthalmology•2022Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 5 Years of Follow-up
Ophthalmology•2022Use of a Novel Microshunt in Refractory Childhood Glaucoma: Initial Experience in a Compassionate Use/Early Access Cohort
Am J Ophthalmol•2022Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up
JAMA Ophthalmol•2021Trabeculotomy Ab Interno With the Trab360 Device for Childhood Glaucomas
Am J Ophthalmol•2020Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized, Controlled Study
Ophthalmology•2016Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study
Ophthalmology•2012Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up
Am J Ophthalmol•2012The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma
Arch Ophthalmol•2002
Certifications & Licensure
- Licensed In
- CA, MA, PA
- License Numbers
- G054094, 51273, MD-041308E


